DOCSLIB.ORG

Prescription Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription Program Prescription Program Drug List — To be used by members who have a three (3) tiered drug plan. Anthem Blue Cross Blue Shield prescription drug benefits include medications available on the Anthem Drug List. Our prescription drug benefits can offer potential savings when your physician prescribes medications on the drug list. MBCEBRO-11-3T Effective 07/13 ANTHEM BLUE CROSS AND BLUE SHIELD DRUG LIST Your prescription drug benefit includes coverage for medicines that you’ll find on the Anthem Drug List. You can often find more savings when your doctor prescribes medicine that is on our drug list. Here are some commonly asked questions and answers about how the drug list works with your prescription drug plan. For more information Q. What is a Drug List? about your drug plan, A. The Anthem Drug List, also called a formulary is a list of U.S. Food and Drug Administration you can do the following: (FDA)-approved brand-name and generic drugs that have been reviewed and recommended for their quality and how well they work. The review is done by the National Pharmacy and • Go to anthem.com Therapeutics (P&T) Process. The P&T Process is performed by an independent group of • Call customer service practicing doctors and pharmacists in charge of the research and decisions surrounding at the number on your our drug list. This group meets regularly to review new and existing drugs and they choose the top drugs for our list—based on their safety, how they work and their value. ID card Because the drugs on our list are reviewed from time to time, it’s a good idea to check • Speech and hearing the list to find out if any drugs have been added or removed. You can do this by going to impaired users anthem.com. (TDD/TTY) should call Q. What are Tiers? 800-221-6915, Monday A. Drugs on the Anthem Drug List are grouped into tiers. There are several factors that are – Friday, 8:30 a.m. – used to determine under which tier a drug will be put in. This can include (but it’s not 5:00 p.m., ET limited to): • Cost of the drug • Bring a copy of this drug • Cost of the drug in comparison to other drugs used for the same type of treatment list to your next doctor’s • Availability of over-the-counter options visit to help you and • Other clinical and cost factors. your doctor select the Q. What is a brand-name drug? lowest cost medicine A. These are drugs that are developed by a company who holds the rights to sell them. When the rights expire, other drug companies can make their own version of the drugs (see generic drugs below). You may be more familiar with brand-name drugs through advertising or because you know people who take them. Q. What is a generic drug? A. Generics are simply copies of brand-name drugs. Brand-name and generic drugs have the same active ingredients, strength and dose. And the FDA requires that generic drugs meet the same high standards for purity, quality, safety and strength. With generics, you get the same quality for less money. Q. What if my doctor or I choose a brand-name drug when a generic version is available? A. In most cases, you would be responsible for the Tier 1 copay plus an additional cost share for the cost difference between the brand-name medication and the generic version. Q. What are “clinically equivalent” medications? How does this affect my drug coverage? KEY FOR DRUG LIST A. When drugs are compared in studies, some drugs have been found to be just as effective as others. These drugs are called “clinically equivalent” so it means they work just as Tier 1 – Lower copayment – Drugs that well. Part of the P&T Process is to review the most current studies to see if multiple drugs offer the greatest value compared to used to treat a disease or a condition have the same effect on a patient. When this is the others that treat the same conditions. case, the Process review team may suggest that we cover only the lower cost drug (so we Some of these are generic versions of can help keep the overall cost of care as low as possible). This means your specific drug brand-name drugs. plan may not cover some drugs (indicated by a ^ symbol next to the drug name) that have Tier 2 – Medium copayment – Brand- clinically equivalent options. name drugs that are generally more affordable. Drugs may also be on this Q. What if my medication is not on the drug list? tier because they are “preferred” A. You may want to first check with your doctor about prescribing a drug that is on the drug among other drugs that treat the same list. If your doctor prescribes a drug that’s not on the drug list, you will need to pay the conditions. This may be based on how copayment that applies to drugs that are not on the list. well they work, if they have less side Q. Can I request that a drug be added to the drug list? effects, if they’re more affordable, etc. A. You or your doctor can put in a request to add a drug to the drug list. You can do this either Tier 3 – Higher copayment – These are in writing or on our website. Requests are reviewed by the P&T Process team during the higher cost brand-name drugs. Some drug list review. Please note that if a drug request is approved, it does not guarantee Tier 3 drugs may have generic versions coverage. Some drugs, such as those used for cosmetic purposes, may be excluded in Tier 1 and may cost more than the from your benefits. Please refer to your insurance Certificate or Evidence of Coverage generic versions on lower tiers. to know for sure. 1 Apri Calcium Acetate Cromolyn Epinastine Fluvoxamine, ER DO, QL Tier 1 Asa/codeine Camrese Cyclobenzaprine Eprosartan QL Folic acid Abacavir Aspirin/caffeine/ Candesartan DO, QL Cyclopentolate Ergotamine Fondaparinux Acarbose butalbital Candesartan/HCTZ Cyclophosphamide Ergotamine/ Fosinopril DO, QL Acebutolol Atenolol DO, QL Cyproheptadine belladonna/PB Fosinopril HCTZ Acetaminophen/caffeine/ Atenolol/chlorthalidone Captopril, HCTZ Danazol Erythromycin Furosemide butalb Atorvastatin DO, QL Carbamazepine, ER Dantrolene Erythromycin base Gabapentin Acetazolamide, SR Atovaquone/proguanil Carbidopa/levodopa Desipramine Erythromycin Galantamine, SR Acetic acid Atropine sulfate Carbidopa/levodopa CR Desloratadine, ODT QL ethylsuccinate Ganciclovir IV Acetic acid/aluminum Aviane Carbidopa/levodopa/ Desmopressin acetate Erythromycin/ Gemfibrozil acetate Azathioprine entacapone Desonide sulfisoxazole Gentamicin Acetic acid/ Azelastine QL Carisoprodol Desoximetasone Escitalopram DO, QL Gianvi hydrocortisone Azelastine nasal QL Carteolol hcl Dexmethylphenidate Estradiol Glimepiride Acetic acid otic Azithromycin QL Cartia XT DO, QL Dextroamphetamine Estradiol/ Glipizide XL Acetylcysteine Bacitracin zinc/ Carvedilol Dextromethorphan/ norethindrone PA Glipizide/metformin Acyclovir cap, tab, oint. polymyxin B Cefaclor guaifenesin Estropipate Glyburide Adapalene Bacitracin/polymyxin/ Cefaclor ER Diazepam Ethambutol Glyburide micronized Ethinyl estradiol/ Adderall XR neomycin-hc opth oint Cefadroxil Diclofenac potassium Glyburide/metformin ethynodiol diacetate Albuterol Baclofen Cefdinir Diclofenac sodium Ophth. Glycolax Cefpodoxime Ethinyl estradiol/ Albuterol/ipratropium Balsalazide Diclofenac, ER Granisetron QL Cefprozil norethindrone Alendronate QL Belladonna/ Diclofenac/misoprostol Griseofulvin phenobarbital Cefuroxime Dicloxacillin Ethosuximide Alfuzosin QL Guaifenesin Benazepril, HCTZ Cephalexin Dicyclomine Etodolac Allopurinol Guaifenesin SR Benzoyl peroxide Cevimeline Didanosine Etodolac ER Alprazolam Guaifenesin/dextrometh Benzoyl peroxide/ Chloral hydrate Diflorasone diacetate Etoposide Amantadine Guaifenesin/hydrocodone Amcinonide clindamycin Chlordiazepoxide Diflunisal Exemestane PA Benzoyl peroxide/ Chlorhexidine gluconate Digoxin Famciclovir Guanabenz Amethia Guanfacine Amethia lo erythromycin Chloroquine 250mg Dihydroergotamine Famotidine Halobetasol Amiloride Benztropine Chlorothiazide nasal spray QL Felbamate Haloperidol Amiloride/ Betamet diprop/prop gyl Chlorphen/pyrilamine/ Diltia XT DO, QL Felodopine DO, QL hydrochlorothiazide Betamethasone phenylephrine Diltiazem Fenofibrate Heparin Aminophylline dipropionate Chlorpheniramine/ Diltiazem CD DO, QL Fenofibric acid Homatropine Amiodarone Betamethasone valerate pseudoephedrine Diltiazem CR DO, QL Fenoprofen Hydralazine Amitriptyline Betaxolol Chlorpromazine tab Diltiazem SR DO, QL Fentanyl PA, QL Hydralazine/HCTZ Amitriptyline/ Bethanechol Chlorpropamide Diphenhydramine 50mg Fexofenadine QL Hydrochlorothiazide chlordiazepoxide Bicalutamide Chlorthalidone Diphenoxylate/atropine Fexofenadine/PSE Hydrocodone Amitriptyline/ Bisoprolol Chlorzoxazone sulfate 12hr QL w/homatropine perphenazine Bisoprolol/HCTZ Cholestyramine, light Dipivefrin HCl Finasteride Hydrocodone/APAP QL Amlodipine DO, QL Brimonidine Chorionic gonadotropin Dipyridamole Flecainide Hydrocodone/ Amlodipine/ Bromfenac Ciclopirox Disopyramide Fluconazole chlorpheniramine atorvastatin DO Bromocriptine Cimetidine Disopyramide CR 150mg Flucytosine Hydrocortisone 2.5% Amlodipine/benazepril Budeprion XL DO, QL Ciprofloxacin QL Disulfiram Fludrocortisone cream, ointment, lotion Amnesteem QL Budesonide 0.25mg/2ml, Citalopram DO, QL Divalproex, ER Flunisolide Nasal Hydrocortisone enema Amphetamine- 0.5mg/2ml QL Clemastine fumarate Donepezil Spray ST, QL Hydrocortisone/ dextroamphetamine Budesonide EC Clindamycin Dorzolamide Fluocinolone acetonide pramoxine Amphetamine- Bumetanide Clobetasol Dorzolamide/timolol Fluocinonide Hydromorphone dextroamphetamine Buprenorphine QL Clomiphene Doxazosin mesylate Fluorometholone Hydroxychloroquine ER ST^# Buprenorphine/naloxone
Load more

Recommended publications
  • It Doesn't Have to Be This Way: Obamacare's Troubling Reality
    It Doesn’t Have to be This Way: Obamacare’s Troubling Reality Every day Americans are confronted with more bad news about Obamacare. Insurers are leaving the ACA marketplaces, premiums continue to increase, and fewer people are enrolling, which will likely lead to more premium increases. Lawmakers must act because the American people deserve better. Insurers Dropping Out CNBC: Anthem will drop out of Ohio's Obamacare market; 18 counties could be left with no ACA plan Alleigh Marré, spokeswoman for the U.S. Department of Health and Human Services, said “This news is heartbreaking for the millions of Ohioans who depend on access to affordable, high-quality healthcare, and this is a stark reminder that Obamacare is collapsing.” Times Free Press: Most of Tennessee will have only one insurer under Obamacare in 2018 Tennessee Insurance Commissioner Julie Mix McPeak said … "the market remains challenged as most Tennessee consumers will still face limited options and increasing premium prices. WTHR: Anthem, MDwise Pulling Out of Indiana’s Obamacare Exchange in 2018 Both companies cited a “volatile” marketplace filled with “growing uncertainty.” So what’s causing this uncertainty? In one word, Obamacare. The flawed design of Obamacare itself, particularly the flawed individual mandate and the instability of the Cost Sharing Reduction subsidies, written and implemented by Democrats, are causing the volatile marketplace. Declining Enrollment Politico: Nearly 2M Fell Off Obamacare Coverage Rolls Through Mid-March CMS said high costs and lack of affordability were the most common factors individuals cited when asked why they didn't keep their coverage. Obamacare’s actual enrollment has failed to meet projections every single year.
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems
    pharmaceutics Review Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems Gemma Latter 1, Jeffrey E. Grice 2, Yousuf Mohammed 2 , Michael S. Roberts 2,3 and Heather A. E. Benson 1,* 1 School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6845, Australia; [email protected] 2 Therapeutics Research Group, The University of Queensland Diamantina Institute, School of Medicine, University of Queensland, Translational Research Institute, Brisbane 4109, Australia; jeff[email protected] (J.E.G.); [email protected] (Y.M.); [email protected] (M.S.R.) 3 School of Pharmacy and Medical Sciences, University of South Australia, Basil Hetzel Institute for Translational Health Research, Adelaide 5011, Australia * Correspondence: [email protected]; Tel.: +61-8-9266-2338 Received: 19 August 2019; Accepted: 17 September 2019; Published: 24 September 2019 Abstract: Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue.
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • Cumulative Irritation Comparison of Adapalene Gel and Solution with 2 Tazarotene Gels and 3 Tretinoin Formulations
    THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Comparison of Adapalene Gel and Solution With 2 Tazarotene Gels and 3 Tretinoin Formulations Alan Greenspan, MD; Christian Loesche, MD; Nancy Vendetti; Kathleen Georgeian; Richard Gilbert, PhD; Michel Poncet, PhD; Michael D. Baker, BS; Pascale Soto, RPh Forty-two subjects with normal skin were enrolled gel 0.025%, and 1 discontinued adapalene in a single-center study to assess the cumula- gel 0.1%. None of the subjects discontinued use tive irritancy potential of adapalene (Differin® of the white petrolatum or the adapalene solu- gel 0.1% and Differin solution 0.1%) compared tion 0.1%. Adapalene gel and solution 0.1% with tazarotene (Tazorac® gels 0.05% and 0.1%), were statistically (PϽ.01) less irritating than tretinoin (Retin-A Micro® gel 0.1%, Avita® cream both tazarotene gels 0.1% and 0.05%, tretinoin 0.025%, and Avita gel 0.025%), and white petro- microsphere gel 0.1%, and tretinoin gel 0.025%, latum (negative control). All test materials were and they were not statistically different from applied randomly, under occlusion, to sites tretinoin gel 0.025%. located on either side of the midline— the mid Cutis. 2003;72:76-81. thoracic area of the subjects’ backs. All patches were applied daily, Monday through Friday, to dapalene (Differin®) is a naphthoic-acid the same sites, unless the degree of reaction to derivative with retinoid activity that is a test product or adhesive necessitated removal A effective in the treatment of mild to moder- (grade 3). ate acne vulgaris.1-4 Adapalene, in both gel and Thirty-eight of the 42 subjects (90.5%) com- cream formulations, at the marketed and approved pleted the study.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • Use of Undiluted Tea-Tree Oil As a Cosmetic
    Federal Institute for Risk Assessment (BfR) Use of undiluted tea-tree oil as a cosmetic Opinion of the Federal Insitute for Risk Assessment (BfR), 1th September 2003 Background Recently there has been an increasing amount of reports on contact-allergic eczema in con- junction with the use of tea-tree oil. Tea-tree oil is sold as a pure natural product, highly con- centrated and undiluted in cosmetics. Tea-tree oil is advertised as a universal remedy al- though there is no marketing authorisation as a pharmaceutical product. Concentrated tea-tree oil has been classified as harmful according to the self-classification of the International Fragrance Association (IFRA) and is labelled with R-phrases R 22 (harmful if swallowed) R 38 (irritating to skin) and R 65 (may cause lung damage if swallowed) as well as the symbol Xn (harmful) (IFRA Labelling Manual 1, 2001). These indications of health hazards are also part of the safety data sheets of raw material suppliers. At the 65th and 66th meetings of the Cosmetics Committee at the Federal Institute for Risk Assessment (BfR), health risks associated with the use of undiluted and highly concentrated tea-tree oil in cosmetic products were discussed extensively. Result Tea-tree oil is a mixture of various terpenes extracted from the Australian tea-tree. Undiluted tea-tree oil is a pure natural product. In the presence of atmospheric oxygen but also when exposed to light and higher temperatures, oxidation processes occur leading to the formation of peroxides, epoxides and endoperoxides which have a sensitising potency and may trigger allergic skin reactions.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Adverse Drug Reactions Sample Chapter
    Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media.
    [Show full text]
  • Formulary Drug Removals
    July 2018 Formulary Drug Removals Below is a list of medicines by drug class that have been removed from your plan’s formulary. If you continue using one of the drugs listed below and identified as a Formulary Drug Removal, you may be required to pay the full cost. If you are currently using one of the formulary drug removals, ask your doctor to choose one of the generic or brand formulary options listed below. Category Formulary Drug Formulary Options Drug Class Removals Allergies BECONASE AQ flunisolide spray, fluticasone spray, mometasone spray, triamcinolone spray, Nasal Steroids / Combinations OMNARIS DYMISTA QNASL ZETONNA Anticonvulsants ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT Anti-infectives, Antibacterials E.E.S. GRANULES erythromycins Erythromycins / Macrolides ERYPED Anti-infectives, Antibacterials MINOCIN minocycline Tetracyclines DORYX doxycycline hyclate DORYX MPC MONODOX Anti-infectives, Antibacterials MACRODANTIN nitrofurantoin Miscellaneous Anti-infectives, Antivirals VALCYTE valganciclovir Cytomegalovirus * Anti-infectives, Antivirals MAVYRET EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI 1 Hepatitis C * DAKLINZA EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6) OLYSIO TECHNIVIE
    [Show full text]
  • Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1
    [CANCER RESEARCH 49, 3168-3172, June 15, 1989] Differential Effects of Tranylcypromine and Imidazole on Mammary Carcinogenesis in Rats Fed Low and High Fat Diets1 David L. McCormick,2 Ann M. Spicer, and Jacqueline L. Hollister Life Sciences Department, IIT Research Institute, Chicago, Illinois 60616 ABSTRACT studies with this class of compounds used inhibitors of the cyclooxygenase pathway of arachidonic acid catabolism; exper Neoplastic development in the rat mammary gland can be suppressed iments performed in our laboratory and by Ip and coworkers by inhibition of the activity of several enzymes involved in eicosanoid biosynthesis. In order to investigate the potential utility of prostacyclin demonstrated that the postcarcinogen phase of rat mammary and thromboxane synthetases as targets for mammary cancer chemopre- carcinogenesis can be suppressed by dietary administration of vention, experiments were conducted to determine the influence of tran- indomethacin (7, 8) or flurbiprofen (9). However, although the ylcypromine (TCP), an inhibitor of prostacyclin synthetase, and ¡mida/ole anticarcinogenic activity of indomethacin is similar to that of (IMI), an inhibitor of thromboxane synthetase, on mammary carcinogen- more widely studied inhibitors of mammary carcinogenesis such esis induced in rats by 7V-methyl-/V-nitrosourea. Fifty-day-old female as retinyl acetate (10) and selenium (11), the dose levels of Sprague-Dawley |Hsd:SD(BR)l rats received a single s.c. dose of 0 or 40 indomethacin required for chemopreventive efficacy in rats are mg of .V-mcth>l-.Y-nitrosoiirea per kg of body weight. Beginning 7 days close to the threshold of lethal toxicity (12). For this reason, after carcinogen administration, groups of rats were fed isoenergetic, studies are ongoing to identify additional modifiers of arachi casein-based diets containing 3 or 20% corn oil (w/w), supplemented with donic acid metabolism whose administration provides an effec (per kg of diet) 10 mg of TCP, 1000 mg of IMI, or sucrose carrier only.
    [Show full text]